Adding Antibiotics to Standard Care Fail to Show Benefit in Large IPF Trial

Adding Antibiotics to Standard Care Fail to Show Benefit in Large IPF Trial

296597

Adding Antibiotics to Standard Care Fail to Show Benefit in Large IPF Trial

Adding two broad spectrum antibiotics — co-trimoxazole or doxycycline — to standard care does not significantly delay hospitalization or prolong survival in adults with idiopathic pulmonary fibrosis (IPF), according to data from one of the largest clinical trials in IPF. While several studies have shown that changes in lung bacteria are associated with IPF progression, these findings highlight the complex nature of this potential link. Based on these findings, which are consistent with data from…

You must be logged in to read/download the full post.